Novo Nordisk (NVO) – Reuters
-
US Senate committee investigates pricing of Novo's Ozempic and Wegovy
-
Novo Nordisk parent refiles US application on Catalent deal
-
Novo Nordisk strikes deal worth up to $1.1 billion to expand cardio business
-
Wegovy to be covered by US Medicare for heart disease patients
-
Novo Nordisk confident of amycretin obesity drug launch this decade
-
Novo Nordisk CEO says innovation in obesity may justify higher price in some segments
-
Novo valuation surpasses Tesla on experimental obesity drug data
-
Novo kidney trial finds Ozempic cuts cardiac deaths in diabetics
-
Novo Nordisk's controlling shareholder plans to invest about $35 billion by 2030
-
Novo Nordisk to begin 2024 share buybacks
-
Novo Nordisk's parent to buy Catalent for $16.5 billion to boost Wegovy supply
-
As Lilly rivalry flares, Novo CEO sets out Wegovy launch strategy
-
European shares see off January muted as falling tech stocks offset healthcare gains
-
Novo Nordisk expects double-digit growth as it boosts Wegovy supplies
-
Novartis misses Q4 profit expectations as costs disappoint
-
Weight loss drug windfall attracts pharma companies
-
Wegovy, Ozempic not linked to increase in suicidal thoughts, US study finds
-
Wegovy maker Novo Nordisk enters research tie-ups with US biotech firms
-
US FDA warns about counterfeit versions of Novo's diabetes drug Ozempic
-
US diabetes patients face delays as insurers tighten Ozempic coverage
-
Novo Nordisk finds compounded Wegovy up to 33% impure, sues Florida pharmacies
-
Lilly's Mounjaro leads to more and faster weight loss than Novo obesity drug, data analysis finds
-
Novo Nordisk shares rise as Wegovy shows heart benefits beyond weight loss
-
Novo Nordisk to discontinue Levemir insulin in U.S. market
-
Lilly weight-loss drug Zepbound gets US, UK approval to rival Wegovy
-
Novo Nordisk, Lilly see insatiable demand for weight-loss drugs
-
Novo Nordisk: 80% of U.S. Wegovy patients with insurance paying less than $25/month
-
Novo Nordisk flags big 2024 sales boost despite Wegovy curbs
-
Medical device makers see limited hit from weight-loss drugs
-
Novo Nordisk in $1.3 billion deal to buy hypertension drug
-
Ozempic's early success in kidney disease trial drags down dialysis stocks
-
U.S. employers covering weight-loss drugs could nearly double in 2024 - survey
-
Novo Nordisk cuts some US supply of obesity drug Wegovy to cope with demand
-
Novo Nordisk to slash US insulin prices, following move by Eli Lilly
-
Novo Nordisk to buy Prothena's heart drug in deal worth up to $1.2 billion
-
Novo Nordisk targets bigger slice of diabetes market with new tablet
-
Lilly's diabetes drug data impresses, hurts rival Novo's shares
-
Novo Nordisk lays off 400 staff in research & development unit
-
Novo Nordisk shares fall after report of layoffs
-
Novo Nordisk says Flexpro PenMate gets FDA approval
Back to NVO Stock Lookup
